Español
Nederlands
Italiano
Deutsch
Français
Português
On July 10, 2025, Qiagen will grant its shareholders a dividend of 0,25 euros per share, in line with a yield of 0.61%.
Investors aiming at Qiagen (QIA) for dividends, remember: the Ex-dividend Date, July 2, 2025, is critical to buy and the Record Date, July 2, 2025, to confirm your participation.
Qiagen NV, listed on major stock exchanges in Germany, Austria, the United States and the United Kingdom, using the symbol QIA as the basis for its stock name, announced its first dividend payment in January 2017, but so far, the company has not paid this interest to its shareholders.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Qiagen Dividends
Dividend calendar of Qiagen
These are the most important events of the Qiagen calendar in 2025:
| Event | Day |
|---|---|
| Last trading date | July 1, 2025 |
| Ex-Dividend (Ex-Date) | July 2, 2025 |
| Record date | July 2, 2025 |
| Date of payment | July 10, 2025 |
Dividend history of Qiagen
In this table you can see the complete history:
| Year | Ex-Dividend | Amount | Total |
|---|---|---|---|
| 2025 | 01/29/2025 | 1.1592721 € | 1.1592721 € |
| 2017 | 01/25/2017 | 1.0243939 € | 1.0243939 € |
Information about Qiagen
Qiagen NV. is a company dedicated to the healthcare industry, specialized in providing technology for molecular diagnostics, is present in more than 35 countries, with headquarters in Hilden, Germany.
It was founded in 1984 by a group of scientists belonging to the Heinrich Heine University of Düsseldorf, launching its first product in 1986, a plasmid purification kit, years later they began a series of important acquisitions that expanded internationally and supported the diversification of its activities, such as Molecular Staging, Inc, Digene in 2004, reaching Shanghai, boosting its diagnostic programs.
They subsequently acquired DxS Ltd, SABiosciences Corp, ESE GmbH, Ipsogen SA, Cellestis Limited, Ingenuity Systems, CLC bio, Exiqon, OmicSoft Corporation, NeuMoDx Inc, Verogen, among others, managing to launch a verified diagnostic test for the detection of H1N1 virus, giving them access to test devices for molecular diagnostics, projecting the QIAsymphony AS and QIAsymphony RGQ platforms, and obtaining QuantiFERON technology for the detection and prevention of diseases, in addition to bioinformatics analysis software.
In 2020, it worked closely with public health authorities and governments to ensure the availability of Covid 19 diagnostic tests, creating low-yield and high-yield kits and tests.
Among its products are molecular samples (tissue, fluids, etc.) with which they can stabilize, extract and purify molecules such as DNA, RNA or proteins, amplified to make them visible for interpretation, being applied in the academic research market, molecular diagnostics, oncology, modulation of the immune response and tests for the detection of infectious diseases.
Frequently asked questions about Qiagen dividends
Qiagen is listed on the Bolsa de Fráncfort and is part of the DAX40.
Qiagen has the Ticker or stock code QIA.
The CEO of Qiagen in 2025 is Mr. Thierry Bernard.